What Ichtholan 50% Treats: Main Uses and Benefits

---

This topical preparation is considered relevant in the supportive context of deep-seated purulent dermatosis, as it is commonly used in situations involving certain distressing symptoms. This topical preparation is applicable within clinical settings that involve acute or disruptive symptom patterns, such as boils (furuncles), certain carbuncles, and localized skin abscesses that have formed a painful, hardened mass.

The ointment is commonly used when short-term symptomatic assistance is needed, as it may be applied in situations involving localized symptoms and supports the management of the lesion's progression. Ichtholan 50% contributes to symptomatic support by assisting with easing the pronounced symptoms of painful induration (the severe hardening of tissue) and the localized pressure associated with the confined symptoms. This support contributes to easing the discomfort and functional strain associated with these acute, deep inflammatory masses.

“It is relevant for managing symptoms that interfere with daily comfort and contributes to improved comfort during periods of heightened symptoms.”

This may assist with maintaining comfort and offers symptomatic relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Support for Painful Induration

• Indication Focus: Conditions characterized by periods of heightened symptoms and deep-seated inflammation.
• Primary Benefit: Contributes to improved comfort by assisting with easing localized pressure and tension.
• Clinical Scenario: Applied when symptoms intensify and supportive relief for hardened, palpable masses may be appropriate.

Regulatory References

1. NIH DailyMed overview on Ichthammol

Official Eligibility Profile for Ichtholan 50%

Eligibility for Ichtholan 50% (Ichthammol Ointment 50%) is defined by regulatory documents based on absolute prohibitions and specific conditional use requirements.

Absolute Contraindication

• Hypersensitivity: The medicine is contraindicated in patients with a known allergy or hypersensitivity to the active substance, Ichthammol (Ammonium bituminosulfonate), or any of the product's excipients.

Age-Related and Conditional Eligibility

Population Group	Regulatory Status
Adults (18+ years)	Generally permitted under standard conditions.
Pediatric Use	Not recommended or restricted in infants and young children due to insufficient safety data.
Pregnant Women	Restricted/Conditional Use; permitted only after a doctor's careful risk-benefit assessment.
Breastfeeding Women	Restricted/Conditional Use; must not be applied to the breast area; use in other areas requires medical assessment.

Specific Restrictions

Official labeling includes constraints related to excipients: patients using latex condoms should avoid applying the ointment to the genital or anal area, as the excipients may compromise condom integrity. Due to the ointment's topical nature and minimal systemic absorption, specific restrictions based on renal or hepatic impairment are typically not noted in the official labeling.

Interactions with other medicines and products

The official regulatory profile for Ichtholan 50% is defined by localized topical interactions and the absence of documented systemic drug-drug interactions. Due to the ointment's dermal route of administration, which results in minimal systemic absorption, no contraindications or restrictions regarding metabolic (e.g., CYP enzyme) or transporter-mediated systemic interactions are specified in the product labeling.

The primary interaction constraints are tied to co-administration on the skin surface. Simultaneous application of other ointments or creams to the same area is not recommended, as this can impair or reduce the effect of Ichtholan 50%. Furthermore, the active ingredient, Ammonium bituminosulfonate, acts as a solubilizing agent, a property that can enhance the absorption of other active substances into the skin when they are used concurrently at the same site.

A specific physical product interaction is formally documented: the excipients (fats and emulsifiers) contained in the ointment can compromise the integrity of latex barrier methods. When Ichtholan 50% is applied to the anal or genital area, these excipients are officially stated to reduce the tear-resistance of latex condoms, which consequently impairs the product's safety.

The action of Ichthammol (Ammonium bituminosulfonate) is a complex, localized, and multi-target pharmacodynamic process strictly confined to the superficial skin layers. It operates across three core mechanistic domains to modulate the tissue environment.

---

Modulating Inflammatory Enzyme Pathways

The primary mechanism involves the localized inhibition of key enzymes in the inflammatory cascade, notably 5-Lipoxygenase (5-LO) and Cyclooxygenase (COX). This interference limits the biosynthesis of potent lipid mediators, such as Leukotrienes and Prostaglandins**, which are responsible for increasing blood vessel permeability and attracting immune cells. This targeted molecular action restricts the formation of mediators responsible for increased vascular permeability and leukocyte infiltration, thereby influencing localized tissue fluid content and erythema.

---

Regulating Dermal Tissue and Fluid Dynamics

The mechanism exerts a keratoplastic action by modulating the cycle of keratinization, which promotes the loosening and shedding of cells in the outer epithelial layer. Simultaneously, the high concentration of the sulfonated substance creates a powerful osmotic gradient on the skin's surface. These actions promote the desquamation of outer epithelial cells and establish an osmotic gradient that drives fluid movement from the interstitial space toward the epidermis.

---

Dampening Peripheral Sensory Signaling

The third domain involves a localized effect on dermal sensory nerve fibers by stabilizing nerve membranes and reducing local mediator concentrations. This mechanistic interference modulates the excitability of peripheral sensory nerve fibers, which affects the neural transmission of pruriceptive and localized nociceptive signals.

How Ichtholan 50% is Used: Administration Guidelines

Ichtholan 50% is described as a preparation intended strictly for topical (dermal) application to the skin's surface. The usage pattern is founded on a specific administration protocol, with the general application schedule established as once daily (1-mal täglich).

Application Procedure and Frequency

The standard application of this ointment is described as consistent across various age groups. The dosing regimen requires applying an adequate amount of the 50% concentration ointment to form a thick layer over the affected dermal area. This is a visual requirement for coverage rather than a fixed mass dose.

A key procedural condition involves occlusion: the treated site must be subsequently covered with a bandage or dressing as specified in the administration instructions. The application timing is flexible and is permitted regardless of the time of day.

Duration and Dressing Management

When the product is used under a permanent dressing as part of a longer therapeutic course, the limit for the dressing is that it must be removed and replaced after 3 days at the latest to maintain proper application conditions. Additionally, any existing ointment residues must be removed from the skin prior to the application of a fresh layer or new dressing. Following these procedures for application, frequency, and dressing management constitutes a standardized approach to using this medicine.

Research evidence / Overview of studies for Ichtholan 50%

---

Evidence for Use in Deep-seated Localized Inflammatory Skin Lesions

Research examining the high-concentration ointment focuses on acute conditions such as boils, skin abscesses, and furuncles. The evidence base is primarily derived from case series and uncontrolled observational studies, which track outcomes in small groups of adult patients in a clinical setting. Studies also included patients with related conditions like Hidradenitis Suppurativa. Findings describe patterns observed regarding changes in the lesions and the time elapsed until a change in lesion status or discharge of contents was observed. Certainty remains low due to the limited evidence and lack of modern Randomized Controlled Trials (RCTs).

Studies on Symptom Measurement and Outcomes Examined

Research examined conditions where outcomes describing episodic or acute changes were relevant, such as pain and localized pressure/tension associated with hard masses (induration). Studies monitored the size of the lesions and tracked the time to a documented event, which is the period until the lesion flattens or discharge occurs. Laboratory investigations also explored the compound's anti-inflammatory activity and its ability to promote skin softening (keratoplastic action). Comparative evidence is lacking, and the evidence quality varies across studies due to inconsistencies in how outcomes were measured.

Long-Term Studies and Follow-up Durations

Studies conducted on this high-concentration ointment focused only on short-term symptom changes due to the acute nature of the target conditions. Consequently, the follow-up durations were limited, typically spanning only a few days to one or two weeks. Long-term effects are not fully established, and the research base does not provide sufficient information on whether any observed patterns continue beyond the acute episode itself.

Evidence in Specific Patient Populations

The available research has focused on adult patients with localized acute conditions. Findings describe group patterns, not personal outcomes, and apply only to the populations studied. There are few data available for specific subgroups, such as children, older adults, or individuals with significant comorbidities. Research does not determine whether an individual in these populations will respond similarly to the patterns observed in the small adult cohorts studied.

Key Scientific Limitations and Areas of Uncertainty

The existing research exhibits several notable limitations. The evidence base relies heavily on case series and observational settings, and there is a lack of large, high-quality RCTs. Furthermore, sample sizes were modest, and some publications do not meet the standards of current rigorous clinical study design. There is also limited data specifically for the 50% concentration, as some studies utilized lower strengths, making it difficult to fully extrapolate all findings. The results reflect the specific conditions under which they were conducted.

Common questions about Ichtholan 50% (FAQ)

Q: Is Ichtholan 50% available over the counter?

A: The regulatory classification of Ichtholan 50% and whether it requires a prescription varies by country. While lower concentrations of Ichthammol products (e.g., 10% or 20%) are commonly available over-the-counter (OTC) in certain regions, the status of the 50% concentration depends on local health authority regulations.

Q: Is Ichtholan 50% a prescription-only medicine?

A: Whether Ichtholan 50% is considered a prescription-only medicine or is available without a prescription is determined by the specific regulatory requirements in each country where it is sold. This classification often relates to the high concentration of the active ingredient.

Q: Is this ointment suitable for use on the face?

A: Official product information emphasizes that Ichtholan 50% must be applied topically only. Use near the eyes is strictly forbidden, and caution is advised regarding all applications to facial skin to ensure compliance with this constraint.

Q: Can Ichtholan 50% be used for acne or pimples?

A: According to regulatory labeling, the product is indicated for the temporary treatment of acute conditions such as boils and abscessing processes (localized, deep-seated infections). General acne or common pimples are not listed as official indications for this product and concentration.

Q: How does Ichtholan 50% differ from other black salves or drawing ointments?

A: Ichtholan 50% is defined by its active ingredient, Ammonium bituminosulfonate, a compound derived from sulfonated shale oils. Regulatory documents classify it as having anti-inflammatory, antibacterial, and circulation-increasing properties with a 'drawing' effect. Official information does not provide comparisons to other proprietary or commercial 'black salves' on the market.

Q: Is Ichtholan 50% the same as Ichthyol?

A: Yes, in pharmacological terms, the active substance in Ichtholan 50% is Ichthammol (Ammonium bituminosulfonate). The term Ichthyol is an older, historically recognized trade or common name often used globally to refer to this same active ingredient.

Q: What is the typical texture and color of the ointment?

A: Official product and safety data describe the product as a dense, semi-solid ointment. The active ingredient, which is derived from bituminous shale oil, gives the product its characteristic dark brown or darkly pigmented color.

Q: Does Ichtholan 50% stain clothing or bedding permanently?

A: Due to its dark color, official product information recommends covering the treated area well to prevent soiling linen and clothing. If stains do occur, the official recommendation for washing is to leave a liquid detergent on the stained area for a longer period of time before cleaning.

Q: Is it normal for the treated area to feel slightly warm?

A: Official safety information documents localized skin irritation, which may include redness, swelling, or pain as an occasional side effect. A specific feeling of warmth is not explicitly listed among the known adverse reactions documented in regulatory sources.

Q: Does Ichtholan 50% have any strong smell?

A: Official safety data confirms that Ichthammol, the active ingredient, has a characteristic odor. This smell is due to its derivation from dark sulfonated shale oil.

Q: Is Ichtholan 50% a product that is commonly sold internationally?

A: Products containing the active substance Ichthammol are sold and regulated globally, including in Europe and the US, in various concentrations. However, the specific 50% strength sold under the brand name Ichtholan is mainly registered and marketed in certain European countries.

Q: Is there official information about using Ichtholan 50% in warm or cold weather?

A: Official regulatory documents specify only that the product should not be stored above 30 C to maintain stability. There are no restrictions noted in the official labeling regarding the environmental temperature during application.

Q: What should I look for to know if the product is expired?

A: All pharmaceutical products are required by regulation to carry an expiration date printed on the packaging, which is the date the product must be used by. To ensure the stability and quality of the ointment, it is used before this date.

Q: What should I do if the ointment seems to dry out or change consistency?

A: Official storage instructions require the container to be kept tightly closed to protect the integrity of the semi-solid preparation. Any change in consistency indicates the quality of the medicine may have been compromised.

Q: Does Ichtholan 50% contain any parabens or common preservatives?

A: The official product documentation lists all excipients (inactive ingredients). The ointment base contains substances such as lanolin and butylated hydroxytoluene (BHT), which functions as an antioxidant to preserve the product.

Q: What should I do if I accidentally swallow a small amount of the ointment?

A: Official product labeling specifies that if the product is accidentally swallowed, immediate medical help or contact with a Poison Control Center is necessary.

How to Store and Dispose of Ichtholan 50% Ointment

Storage and disposal procedures for Ichtholan 50% must align strictly with the requirements outlined in official regulatory labeling.

Storage Conditions

• Temperature: Do not store the ointment above 30°C.
• Container Protection: The container must be kept tightly closed to protect the integrity and stability of the semi-solid preparation.
• Child Safety: Like all medicines, the product must be kept out of the sight and reach of children.

Disposal Instructions

Official regulatory documents state that there are no special requirements for the disposal of used medicinal product or waste materials derived from Ichtholan 50%.

Disposal of any unused or expired ointment should be carried out in accordance with local requirements for pharmaceutical waste.